**FOI Ref: 6383**

**Category(ies): Clinical - Drugs**

**Subject: Biologic Drugs in Dermatology and Gastroenterology**

**Date Received: 11/05/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| I have a freedom of information request regarding the use of Biologic medicines. Could you please answer the following two questions? | |
| 1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:  * Adalimumab - Humira * Adalimumab Biosimilar * Apremilast * Bimekizumab * Brodalumab * Certolizumab * Dimethyl fumarate * Etanercept - Enbrel * Etanercept Biosimilar * Guselkumab * Infliximab - Remicade * Infliximab Biosimilar * Ixekizumab * Risankizumab * Secukinumab * Tildrakizumab * Ustekinumab | * Adalimumab – Humira - 0 * Adalimumab Biosimilar - 35 * Apremilast - 0 * Bimekizumab - 0 * Brodalumab - 2 * Certolizumab - 3 * Dimethyl fumarate - 0 * Etanercept – Enbrel - 0 * Etanercept Biosimilar - 0 * Guselkumab - 32 * Infliximab – Remicade - 0 * Infliximab Biosimilar - 0 * Ixekizumab - 5 * Risankizumab - 8 * Secukinumab - 26 * Tildrakizumab - 0 * Ustekinumab - 33 |
| 1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:  * Adalimumab - Humira * Adalimumab Biosimilar * Filgotinib * Golimumab * Infliximab - Remicade * Infliximab Biosimilar * Ozanimod * Tofacitinib * Ustekinumab * Vedolizumab | * Adalimumab – Humira - 10 * Adalimumab Biosimilar - 53 * Filgotinib - 0 * Golimumab - 0 * Infliximab – Remicade - 1 * Infliximab Biosimilar - 39 * Ozanimod - 0 * Tofacitinib - 0 * Ustekinumab - 14 * Vedolizumab - 45 |